SWOG1207 Adjuvant Hormone Therapy ±1 Year of Everolimus

SWOG S1207 - Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer. e3 Breast Cancer Study- Evaluating Everolimus with Endocrine Therapy

November 22, 2017

  • Clinical Trial Information

    Trial Contact: Pelley, Jennifer

    Trial Phone: 321.841.4348

  • IRB No: S1207

    Protocol Abbrev: S1207

    Principal Investigator: Nikita Chandrakant Shah, MD

    Sub Investigators: Baidas, Said MD; Mamounas, Eleftherios MD; Moroose, Rebecca MD; Rostorfer, Regan MD

    Phase: Drug: Phase III

    Age Group: Adult

    Secondary Protocol No: SWOG S1207

    Treatment: Chemotherapy

    Applicable Disease Sites: Breast

    Therapies Involved: Drug: anastrozole Drug: everolimus Drug: exemestane Drug: goserelin acetate Drug: letrozole Drug: leuprolide acetate Drug: tamoxifen citrate Other: placebo

    ClinicalTrials.gov ID: NCT01674140

  • Objective

    To compare whether the addition of 1 year of everolimus to standard adjuvant endocrine therapy reduces recurrence in patients with hormone positive HER2 negative breast cancer.

  • Key Eligibility

    Hormone positive and HER 2 negative breast cancer and must have completed surgery and axillary staging